YN340031 JAK3-IN-6 1443235-95-7

Selective JAK3 inhibitor 1 is an irreversible JAK3 inhibitor with Ki values of 0.07 nM, 320 nM, 740 nM for JAK3, JAK1 and JAK2 respectively. It is also selective over the other kinases possessing a cysteine in th...

YN320359 CCG-203971 1443437-74-8

CCG-203971 is a novel small-molecule inhibitor of the Rho/MRTF/SRF pathway with the IC50 value of 0.64 μM for SRE.L. It inhibits Rho-mediated gene transcription.

YN251796 Aviptadil acetate 1444827-29-5

Aviptadil acetate is an analogvasoactive intestinal polypeptide (VIP)with potentvasodilatoryeffects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil aceta...

YN320457 GPR84 antagonist 8 1445846-30-9

GPR84 antagonist 8 is a selectiveGPR84antagonist.

YN320751 GLPG1205 1445847-37-9

GLPG1205 is potent, selective and orally activeGPR84(a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis.

YN340080 SHR0302 1445987-21-2

SHR0302 is a potent and orally active all members of theJAK familyinhibitor, particularlyJAK1. The selectivity of SHR0302 forJAK1is >10-fold forJAK2, 77-fold forJAK3, 420-fold forTyk2. SHR0302 inhibitsJAK1-ST...

YN440366 RO9021 1446790-62-0

RO9021 potently inhibits SYK kinase activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.

YN260240 m-PEG6-NHS ester 1449390-12-8

m-PEG6-NHS ester is a non-cleavable 5 unit PEGADClinker used in the synthesis of antibody-drug conjugates (ADCs).

YN370449 Rovazolac 1454288-88-0

Rovazolac is aliver x receptor (LXR)modulator extracted from patent WO2013130892A1.

YN480677 LP-935509 1454555-29-3

LP-935509 is a selective, ATP-competitive and brain-penetrant inhibitor ofadapter protein-2 associated kinase 1 (AAK1)with an IC50 and a Ki of 3.3nM and 0.9nM, respectively. LP-935509 is also a potent inhibitor of BIK...

YN330324 HG-9-91-01 1456858-58-4

HG-9-91-01 (SIK inhibitor 1) is a potent and highly selective inhibitor of salt-inducible kinase (SIK) with IC50 of 0.92 nM, 6.6 nM and 9.6 nM for SIK1, SIK2 and SIK3, respectively.

YN371619 LS-102 1456891-34-1

LS-102 is a selective E3 ubiquitin ligasesynoviolin (Syvn1)inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of 35μM. LS-102 has the potential for rheumatoid arthritis treatment.

YN450030 Adavivint 1467093-03-3

SM04690 is a potent and specific inhibitor of canonical Wnt signaling with an EC50 of 19.5 nM for inhibiting the TCF/LEF reporter. It is ∼150- to 500-fold more potent than the other known Wnt inhibitors across multiple...

YN330181 Omaveloxolone 1474034-05-3

Omaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.

YN372576 GSK2981278 1474110-21-8

GSK2981278 is a highly potent and selective inverse agonist for RORγ .

YN270377 RIPK1-IN-4 1481641-08-0

RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor ofreceptor interacting protein 1 (RIP1)kinase and binds to a DLG-out inactive form of RIP1 with anIC50s of 16nM and 10nM for RIP1 and ...

YN251271 Cefalonium hydrate 1486466-27-6

Cefalonium hydrate is the first-generation β-lactam cephalosporin antibiotic that is widely used to research bovine mastitis caused by Gram-positive bacteria including staphylococci .

YN483868 Cyclosporin A-Derivative 1 1487360-85-9

Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit ...

YN440221 Syk-IN-1 1491150-77-6

Syk-IN-1 (compound 4) is a potentSykinhibitor, with an IC50 of 35nM.

YN430085 BC-1215 1507370-20-8

BC-1215 is an inhibitor ofF-box protein 3(FBXO3, a ubiquitin E3 ligase component,IC50=0.9 μg/mL for IL-1β release). BC-1215 decreases Fbxo3-Fbxl2 interaction and prevents SCFFbxo3catalyzed Fbxl2 ubiquitination. BC...